NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
01/13/2026
Back to search
Official data from USPTO
ESTEVE PHARMACEUTICALS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
ESTEVE PHARMACEUTICALS
ST13
US500000099044353Class
5
Filing
99044353
Registration
8099251
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
20
Latest update
01/13/2026
Trademark type
Word
Nice classes
5
Filing date
02/17/2025
Registration date
01/13/2026
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
01/13/2026
Last transaction
01/13/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
85
Owner location
Barcelona, ES
Examiner
LOTT, MAUREEN DALL
Law office
L50
Current location
FILE REPOSITORY (FRANCONIA)
Holders and representatives
Holders
ESTEVE PHARMACEUTICALS, S.A.
Representatives
G Patrick SAGE II HUESCHEN AND SAGE PLLC
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations for the treatment of metabolic disordersfor treating diabeteshypoglycaemiagoutosteoarthritismuscular dystrophyanemiabulimia nervosaanorexiaobesity and hypothyroidism; Pharmaceutical preparations for the treatment of the endocrine systemfor treating growth and thyroid disorders; Pharmaceutical preparations for the treatment of the musculoskeletal systemfor treating connective tissue diseasesbone diseasesspinal diseasesback painfracturessprainscartilage injuries; Pharmaceutical preparations for the treatment of genitourinary diseasesfor treating urological diseasesinfertilitysexually transmitted diseasesinflammatory pelvic diseases; Pharmaceutical preparations for the treatment of neurological diseasesfor use in treating Alzheimer's diseaseHuntington's diseasecerebral palsybrain injuriesspinal cord injuriesseizure disorders; Pharmaceutical preparations for the treatment of hormonal disorderscorticosteroidshormone replacement therapy preparationsoral contraceptivesthyroid hormone preparations; Pharmaceutical preparations for the treatment of psychiatric diseasesfor treating mood disordersanxiety disorderscognitive disordersschizophrenia and bipolar disorders; Pharmaceutical preparations for the treatment of cardiovascularcardiopulmonarysexual dysfunctiononcologicalhepatologicalophthalmicrespiratorygastrointestinalimmune system related diseases and disorders; Pharmaceutical preparations for use in dermatologyfor use in treating dermatitiseczemapsoriasisskin pigmentation diseasesdermatological sexually transmitted diseases
Publications
History of USPTO decisions and trademark events.
20 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
01/13/2026
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
11/25/2025
PUBO
PUBLISHED FOR OPPOSITION
11/25/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
11/19/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
10/27/2025
XAEC
EXAMINER'S AMENDMENT ENTERED
10/27/2025
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
10/27/2025
GNEA
EXAMINERS AMENDMENT E-MAILED
10/27/2025
CNEA
EXAMINERS AMENDMENT -WRITTEN
10/27/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
10/24/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
10/24/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
10/24/2025
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
07/26/2025
GNRT
NON-FINAL ACTION E-MAILED
07/26/2025
CNRT
NON-FINAL ACTION WRITTEN
07/26/2025
DOCK
ASSIGNED TO EXAMINER
07/23/2025
MAFR
APPLICATION FILING RECEIPT MAILED
02/17/2025
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
02/17/2025
NWAP
NEW APPLICATION ENTERED
02/17/2025
Continuous trademark protection
Get notified about every new filing that threatens ESTEVE PHARMACEUTICALS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.